

Curriculum Vitae

Personal information **CRISTINA BENITO SASTRE**

Work experience

1. Employer: AEMPS
 - Start date: 05/2022
 - End date:
 - Position: Assessor of biologicals-immuno veterinary medicines
 - Activities: _Assessment of quality, efficacy and safety of marketing authorizations, renewals and/or variations of immunological/biological medicines and new veterinary therapies submitted by centralised, mutual recognition and decentralised European procedures, and by national procedures. _Assessment of European and national scientific advice, and research products and national clinical trials with these products.
 - Country: Spain
2. Employer: ASPHALION
 - Start date: 06/2021
 - End date: 04/2022
 - Position: Scientific and Regulatory Affairs Officer
 - Activities: _ eCTD writing (module 2) for human medicines _ Promotional materials reviewing
 - Country: Spain
3. Employer: AEMPS
 - Start date: 04/2021
 - End date: 06/2021
 - Position: Clinical Assessor
 - Activities: _ Assessment of product information templates (Summary of product characteristics, labelling and package leaflet) _ Post_opinion linguistic reviewing of the product information of centrally authorised products
 - Country: Spain
4. Employer: AEMPS
 - Start date: 09/2020
 - End date: 04/2021
 - Position: Coordinator of variations for DC/MR procedures
 - Activities: Coordination of mutual recognition and decentralised variation procedures
 - Country: Spain
5. Employer: University College London
 - Start date: 02/2012
 - End date: 04/2016
 - Position: Research Associate
 - Activities:
 - Country: United Kingdom
6. Employer: Complutense University of Madrid
 - Start date: 01/2011
 - End date: 01/2012
 - Position: Postdoctoral researcher
 - Activities:
 - Country: Spain
7. Employer: CIBERNED
 - Start date: 07/2008
 - End date: 12/2010
 - Position: Researcher
 - Activities:
 - Country: Spain
8. Employer: FUNDACIÓN HOSPITAL ALCORCÓN
 - Start date: 02/2002
 - End date: 11/2007
 - Position: PhD Student
 - Activities:
 - Country: Spain

Education and training

1. Subject: European Regulatory Affairs postgraduate course Colegio Oficial de farmaceúticos de Madrid
 - Start date: 10/2019
 - End date: 03/2020
 - Qualification: Postgraduate
 - Organisation: Colegio Oficial de farmaceúticos de Madrid
 - Country: Spain
2. Subject: PhD in Biochemistry and Molecular Biology
 - Start date: 10/2003
 - End date: 12/2009
 - Qualification: PhD
 - Organisation: Complutense University of Madrid
 - Country: Spain
3. Subject: BSc in Chemistry Sciences

- Start date: 09/1995
- End date: 09/2000
- Qualification: BSc
- Organisation: Autonoma University of Madrid
- Country: Spain

Additional information

Publications

Peer_Review Journals 1. Wagstaff LJ, Gomez_Sanchez JA, Fazal SV, Otto GW, Kilpatrick AM, Michael K, Wong LYN, Ma KH, Turmaine M, Svaren J, Gordon T, Arthur_Farraj P, Velasco_Aviles S, Cabedo H, Benito C, Mirsky R, Jessen KR. Failures of nerve regeneration caused by aging or chronic denervation are rescued by restoring Schwann cell c_Jun. *Elife*, Jan 21;10:e62232. doi: 10.7554/eLife.62232 (2021). 2. Miller S.R., Benito C., Mirsky R., Jessen K.R., Baker C.V.H. Neural crest Notch/Rbpj signalling regulates olfactory gliogenesis and neuronal migration. *Genesis*, 56(6-7) (2018). 3. Gómez_Sánchez JA, Pilch KS, van der Lans M, Fazal SV, Benito C, Wagstaff LJ, Mirsky R, Jessen KR. After nerve injury, lineage tracing shows that myelin and Remak Schwann cells elongate extensively and branch to form repair Schwann cells, which shorten radically on remyelination. *The Journal of Neuroscience*, 37(37):9086_9099 (2017). 4. Benito C, Davis CM, Gómez_Sánchez JA, Turmaine M, Meijer D, Poli V, Mirsky R, Jessen KR. STAT3 controls the long-term survival and phenotype of repair Schwann cells during nerve regeneration. *The Journal of Neuroscience*, 37(16):4255_4269. (2017). 5. Miller SR, Perera SN, Benito C, Scott SR, Baker CV. Evidence for a Notch_1 mediated transition during olfactory ensheathing cell development. *J Anat*, 229(3):369_383. (2016). 6. Chiarlone A, Bellocchio L, Blázquez C, Resel E, Soria_Gómez E, Cannich A, Ferrero JJ, Sagredo O, Benito C, Romero J, Sánchez_Prieto J, Lutz B, Fernández_Ruiz J, Galve_Roperh I, Guzmán M. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. *Proc Natl Acad Sci USA*, 111(22):8257_62 (2014). 7. Rodríguez_Cueto C, Benito C, Romero J, Hernández_Gálvez M, Gómez_Ruiz J, Fernández_Ruiz J. Endocannabinoid_hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias. *Pathobiology*, 81(3):149_59 (2014). 8. Rodríguez_Cueto C, Benito C, Fernández_Ruiz J, Romero J, Hernández_Gálvez M, Gómez_Ruiz M. Changes in the CB1 and CB2 receptors in the postmortem cerebellum of humans affected by spinocerebellar ataxias. *Br J Pharmacol*, 171(6):1472_89 (2014). 9. Benito C, Tolón RM, Castillo AI, Ruiz_Valdepeñas L, Martínez_Orgado JA, Fernández_Sánchez FJ, Vázquez C, Cravatt BF, Romero J. Beta Amyloid exacerbates inflammation in astrocytes lacking Fatty Acid Amide Hydrolase through a mechanism involving PPAR_α, PPAR_γ and TRPV1, but not CB1 or CB2 Receptors. *Br J Pharmacol*, 166(4):1474_1489 (2012). 10. Ruiz_Valdepeñas L, Martínez_Orgado JA, Benito C, Millán A, Tolón RM, Romero J. Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. *J Neuroinflammation*, 18;8(1):5 (2011). 11. Blázquez C., Chiarlone A., Sagredo O., Aguado T., Pazos M.R., Resel E., Palazuelos J., Julien B., Salazar M., Börner C., Benito C., Carrasco C., Diez_Zaera M., Paoletti P., Díaz_Hernández M., Ruiz C., Sendtner M., Lucas J.J., de Yébenes J.G., Marsicano G., Monory K., Lutz B., Romero J., Alberch J., Ginés S., Kraus J., Fernández_Ruiz J., Galve_Roperh I., Guzmán M. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. *Brain*, 134(Pt 1):119_36 (2011). 12. Ruiz_Valdepeñas L., Benito C., Tolón R.M., Romero J. The endocannabinoid system and amyloid-related diseases. *Exp Neurol*, 224(1):66_73 (2010). 13. Palazuelos J., Aguado T., Pazos M.R., Julien B., Carrasco C., Resel E., Sagredo O., Benito C., Romero J., Azcoitia I., Fernández_Ruiz J., Guzmán M., Galve_Roperh I. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. *Brain*, 132(Pt 11):3152_3164 (2009). 14. Tolón R.M., Núñez E., Pazos M.R., Benito C., Castillo A.I., Martínez_Orgado J.A., Romero J. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. *Brain Res*, 1283:148_154 (2009). 15. Sagredo O., González S., Arroyo I., Pazos M.R., Benito C., Lastres-Becker I., Romero J.P., Tolón R.M., Mechoulam R., Brouillet E., Romero J., Fernández_Ruiz J. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. *Glia*, 57(11):1154_1167 (2009). 16. Rosado A., Tejedor M.A., Benito C., Cárdenas R., González_Mancebo E. Occupational asthma caused by octopus particles. *Allergy*, 64(7):1101_1102 (2009). 17. Fernández_Rivas M., Benito C., González_Mancebo E., Alonso Díaz de Durana M.D. Educational case series: Allergies to fruits & vegetables. *Pediatr Allergy Immunol*, 19(8):675_681 (2008). 18. Palazuelos J., Davoust N., Julien B., Hatterer E., Aguado T., Mechoulam R., Benito C., Romero J., Silva A., Guzmán M., Nataf S., Galve_Roperh I. The CB2 cannabinoid receptor controls myeloid progenitor trafficking. Involvement in the pathogenesis of an animal model of multiple sclerosis. *J Biol Chem*, 283(19):13320_13329 (2008). 19. Pazos M.R., Tolón R.M., Benito C., Rodríguez C.F., Gorgojo J.J., Nevado M., Álvarez M., Arias F., Almodóvar F., Fernández M.T., Lledó J.L., González S., Fernández_Ruiz J., Romero J. Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa. *J Histochem Cytochem*, 56(5):511_516 (2008). 20. Núñez E., Benito C., Tolón R.M., Hillard C.J., Griffin W.S.T., Romero J. Glial expression of cannabinoid CB2 receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. *Neuroscience*, 151:104_110 (2008). 21. Benito C., Tolón R.M., Pazos M.R., Núñez E., Castillo A.I., Romero J. Cannabinoid CB2 receptors in human brain inflammation. *Br J Pharmacol*, 153:277_285 (2008). 22. Benito C., Núñez E., Pazos M.R., Tolón R.M., Romero J. The endocannabinoid system and Alzheimer's disease. *Mol Neurobiol*, 36(1):75_81 (2007). 23. Benito C., González_Mancebo E., Alonso Díaz de Durana M. D., Tolón R. M., Fernández_Rivas M. Identification of a 7S globulin as a novel coconut allergen. *Ann Allergy Asthma Immunol*, 98(6):580_584 (2007). 24. Benito C., Romero J.P., Tolón R.M., Clemente D., Docagne F., Hillard C.J., Guaza C., Romero J. Cannabinoid CB1 and CB2 receptors and Fatty Acid Amide Hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. *The Journal of Neuroscience*, 27(9):2396_2402 (2007). 25. Pazos M.R., Núñez E., Benito C., Tolón R.M., Romero J. Functional neuroanatomy of the Endocannabinoid System. *Pharmacol Biochem Behav*, 81(2):239_47 (2005). 26. Benito C., Kim W.K., Chavarría I., Hillard C.J., Mackie K., Tolón R.M., Williams K., Romero J. A glial endogenous cannabinoid system is up-regulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. *The Journal of Neuroscience*, 25(10): 2530_2536 (2005). 27. Núñez E., Benito C., Pazos M.R., Tolón R.M., Barbachano A., Fajardo O., González S., and Romero J. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study. *Synapse*, 53: 208_213 (2004). 28. Pazos M.R., Núñez E., Benito C., Tolón R.M., Romero J. Role of the Endocannabinoid System in Alzheimer's disease: new perspectives. *Life Science*, 75: 1907_1915 (2004). 29. Benito C., Núñez E., Tolón R., Carrier E. J., Rábano A., Hillard C. J., Romero J. Cannabinoid CB2 receptor and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. *The Journal of Neuroscience*, 23(35): 11136_11141 (2003). 30. Fernández_Rivas M., González_Mancebo E., Rodríguez_Pérez R., Benito C., Sánchez_Monge R., Salcedo G., Alonso M.D., Rosado A., Tejedor M.A., Vila C., Casas M.L. Clinically relevant peach allergy is related to peach lipid transfer protein, Pru p3, in the Spanish population. *J Allergy Clin Immunol*, 112(4): 789_795 (2003). BOOK CHAPTERS 1. Romero J., Tolón R.M., Benito C. "Potencial de los cannabinoides en la enfermedad de Alzheimer". Actualización sobre el potencial terapéutico de los cannabinoides. JA Ramos y J Fernández_Ruiz (ed), Agencia Antidroga de la Comunidad de Madrid, pp127_140. (2009). 2. Benito C., Tolón R.M., Núñez E., Pazos M.R., Romero J. "Neuroinflammation and the glial endocannabinoid system". Cannabinoids and the Brain. Attila Kofalvi (ed), Springer Verlag, pp. 331_359. (2007) (DOI:10.1007/978_0_387_74349_3_16). 3. Fernández_Rivas M., Benito C. "Alergia a conejo". Sesiones Interhospitalarias Sociedad Madrid-Castilla la Mancha de Alergología e Inmunología Clínica. Nº 14. Curso 2004_2005. Luzán S S.A. (ed), pp. 27_34.

Projects

Memberships

AWARD _ 2010 _ Juan Abello Pascual I thesis award in the Biochemistry area. Real Academia de Doctores de España FELLOWSHIPS _ 2011_2012. Postdoctoral "Juan de la Cierva" Researcher (JCI_2010_06909). Biochemistry and Molecular Biology Dept., Faculty of Medicine, Complutense University of Madrid (Spain). _ 2012_2014. Postdoctoral "Marie Curie Intra-European Fellowship" (FP7_PEOPLE_2010_IEF). Cell and Developmental Biology Dept., University College London (UK). MEMBERSHIP OF SOCIETIES: _ 2003_2018 Spanish Cannabinoid Research Society (SEIC) _ 2004_2007 European Academy of Allergy and Clinical Immunology (EAACI) _ 2005_2011 and 2016_2018 Society for Neuroscience (SfN) _ 2005_2017 International Cannabinoid Research Society (ICRS) _ 2012_2017 Society of Spanish Researchers in the United Kingdom (SRUK)

Other Relevant Information

COURSES _2022. ADVANCED THERAPIES: SCIENTIFIC BASIS AND CLINICAL USE (30 hours). Murcia University (Spain) _ 2002. BIOMEDICINAL TECHNIQUES (213 hours). Medicine Faculty of Alcala de Henares University, Madrid (Spain). _ 2001. GENE REGULATION AND GENE THERAPY (111 hours). Centro de Biología Molecular Severo Ochoa. Consejo Superior de Investigaciones Científicas (CSIC). Autonomous University, Madrid (Spain).